Phase 1, 2 countries, 3 clinics
In a global first, Prism Research joins Nucleus Network to become the only Phase 1 clinical trials provider to provide the flexibility of clinics in both Australia and the United States.
With the acquisition of US-based Prism, Nucleus Network is in the unique position of offering biotechs, pharmaceutical companies and CROs three separate specialized Phase 1 clinics. “Our clients have long valued our speed, quality and value, and we now enhance this by offering specialized services across three geographically diverse clinics,” says Nucleus network CEO Cameron Johnson.
“In Australia, we offer first-in-human healthy patient studies in Melbourne, and biosimilars and infectious diseases specialization in Brisbane. These clinics are located within two of Australia’s largest teaching hospitals,” adds Cameron.
“Our third clinic, Prism Research, is located within the Medical Alley hub of Minnesota, and offers specialized Renal, Hepatic and numerous other patient population Phase 1 trials. Together, we now offer over 200 beds of specialized Phase 1 clinical trials expertise across two countries.”